| 参考文献: |
1. Daemen A, et al. ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models[J]. Cancer Research, 2024, 84(6_Supplement): 6586-6586.2. ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones |